MannKind (MNKD) said Wednesday that it has completed patient randomization in its US Phase 1b INFLO-1 clinical trial evaluating nintedanib DPI for idiopathic pulmonary fibrosis, a chronic lung disease.
MannKind said it expects to report data from the INFLO-1 study in Q3, providing an initial clinical assessment of safety, tolerability, and pharmacokinetics in patients with idiopathic pulmonary fibrosis.
Additionally, the company said it has enrolled the first of an expected 210 participants in its global Phase 2 INFLO-2 study, set to be conducted across about 85 sites.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments